These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
683 related articles for article (PubMed ID: 17517082)
1. Prevalence of occult metastatic disease in patients undergoing 18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules. Lee ST; Berlangieri SU; Poon AM; Mitchell P; Pathmaraj K; Tabone K; Byrne AJ; O'Keefe GJ; Knight SR; Clarke CP; Scott AM Intern Med J; 2007 Nov; 37(11):753-9. PubMed ID: 17517082 [TBL] [Abstract][Full Text] [Related]
2. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer? Aquino SL; Fischman AJ Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753 [TBL] [Abstract][Full Text] [Related]
3. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Daniels CE; Lowe VJ; Aubry MC; Allen MS; Jett JR Chest; 2007 Jan; 131(1):255-60. PubMed ID: 17218584 [TBL] [Abstract][Full Text] [Related]
4. Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT. Christensen JA; Nathan MA; Mullan BP; Hartman TE; Swensen SJ; Lowe VJ AJR Am J Roentgenol; 2006 Nov; 187(5):1361-7. PubMed ID: 17056930 [TBL] [Abstract][Full Text] [Related]
5. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET. Hsieh HJ; Lin SH; Lin KH; Lee CY; Chang CP; Wang SJ Ann Nucl Med; 2008 Jul; 22(6):533-8. PubMed ID: 18670862 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. Dewan NA; Gupta NC; Redepenning LS; Phalen JJ; Frick MP Chest; 1993 Oct; 104(4):997-1002. PubMed ID: 8404239 [TBL] [Abstract][Full Text] [Related]
7. Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan. Dewan NA; Shehan CJ; Reeb SD; Gobar LS; Scott WJ; Ryschon K Chest; 1997 Aug; 112(2):416-22. PubMed ID: 9266877 [TBL] [Abstract][Full Text] [Related]
9. Fluoro-deoxy-glucose positron emission tomography for evaluation of indeterminate lung nodules: assigning a probability of malignancy may be preferable to binary readings. Kim SC; Machac J; Krynyckyi BR; Knesaurek K; Krellenstein D; Schultz B; Gribetz A; DePalo L; Teirstein A; Kim CK Ann Nucl Med; 2008 Apr; 22(3):165-70. PubMed ID: 18498030 [TBL] [Abstract][Full Text] [Related]
10. The sensitivity of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of metastatic pulmonary nodules. Fortes DL; Allen MS; Lowe VJ; Shen KR; Wigle DA; Cassivi SD; Nichols FC; Deschamps C Eur J Cardiothorac Surg; 2008 Dec; 34(6):1223-7. PubMed ID: 18848459 [TBL] [Abstract][Full Text] [Related]
11. Occult lung infarction may induce false interpretation of 18F-FDG PET in primary staging of pulmonary malignancies. Kamel EM; McKee TA; Calcagni ML; Schmidt S; Markl S; Castaldo S; Delaloye AB Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):641-6. PubMed ID: 15726357 [TBL] [Abstract][Full Text] [Related]
12. Predictive value of dual-time Pahk K; Chung JH; Kim S; Lee SH Tumori; 2018 Jun; 104(3):207-212. PubMed ID: 29714664 [TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of imaging proliferative activity in lung nodules. Buck AK; Hetzel M; Schirrmeister H; Halter G; Möller P; Kratochwil C; Wahl A; Glatting G; Mottaghy FM; Mattfeldt T; Neumaier B; Reske SN Eur J Nucl Med Mol Imaging; 2005 May; 32(5):525-33. PubMed ID: 15599526 [TBL] [Abstract][Full Text] [Related]
14. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Bryant AS; Cerfolio RJ Ann Thorac Surg; 2006 Sep; 82(3):1016-20. PubMed ID: 16928527 [TBL] [Abstract][Full Text] [Related]
15. Solitary pulmonary nodule evaluation in regions endemic for infectious diseases: Do regional variations impact the effectiveness of fluorodeoxyglucose positron emission tomography/computed tomography. Purandare NC; Pramesh CS; Agarwal JP; Agrawal A; Shah S; Prabhash K; Karimundackal G; Jiwnani S; Tandon S; Rangarajan V Indian J Cancer; 2017; 54(1):271-275. PubMed ID: 29199704 [TBL] [Abstract][Full Text] [Related]
16. Clinical significance of small pulmonary nodules with little or no 18F-FDG uptake on PET/CT images of patients with nonthoracic malignancies. O JH; Yoo IeR; Kim SH; Sohn HS; Chung SK J Nucl Med; 2007 Jan; 48(1):15-21. PubMed ID: 17204694 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of dual-time 18F-FDG PET in the diagnosis of pulmonary nodules: a meta-analysis. Barger RL; Nandalur KR Acad Radiol; 2012 Feb; 19(2):153-8. PubMed ID: 22104289 [TBL] [Abstract][Full Text] [Related]
18. Noninvasive diagnosis of solitary pulmonary lesions in cancer patients based on 2-fluoro-2-deoxy-D-glucose avidity on positron emission tomography/computed tomography. Bar-Shalom R; Kagna O; Israel O; Guralnik L Cancer; 2008 Dec; 113(11):3213-21. PubMed ID: 18924145 [TBL] [Abstract][Full Text] [Related]
19. Clinical utility of F-18 FDG PET-CT in the initial evaluation of lung cancer. Madsen PH; Holdgaard PC; Christensen JB; Høilund-Carlsen PF Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2084-97. PubMed ID: 27164899 [TBL] [Abstract][Full Text] [Related]